Mashup Score:1
events.lls.org2021 Scenic Shore Bike Tour - 1 day
Mashup Score:1
Twitter Feed: Mike Thompson, MD, PhD, FASCO
Mashup Score:1
OUP AcademicAbstractObjective. To identify needs in a clinical decision support tool development by exploring how primary care providers currently collect and use family...
-
Physicians’ strategies for using family history data: having the data is not the same as using the data [Oct 8, 2020] Taber et al. @JAMIA_Open https://t.co/ObpT4SRVhY #geneticcounselors - view on twitter
More coverage:
#geneticcounselors
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and...
-
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/g3GP7EsUeS - view on twitter
Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who...
-
Current @eaonc Multiple Myeloma Studies https://t.co/x4yXjab8MR #mmsm #EAonc cc @VincentRK https://t.co/x4yXjab8MR - view on twitter
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial – Full Text...
-
Ph3 Len +/- Ixa maintenance for MRD+ s/p ASCT -> #EAOnc EAA171 - Optimizing Prolonged Treatment In Myeloma Using MRD assessment (OPTIMUM) [Activation: Jun 1, 2021] https://t.co/4TRHkoLglI PI= @myelomaMD #NCT03941860 @eaonc #mmMRD #mmsm #bmtsm n=510 https://t.co/4TRHkoLglI - view on twitter
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma – Full Text...
-
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/VtBMJUjI5X - view on twitter
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial – Full Text...
-
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/qD26HMx3J8 - view on twitter
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2,...
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/IeLcOehWrr - view on twitter
The DNA damage response (DDR) is now known to play an important role in both cancer development and its treatment. Targeting proteins such as...
-
Progress towards a clinically-successful ATR inhibitor for cancer therapy [Feb 5, 2021] @barnieh_m et al. Current Research in Pharmacology and Drug Discovery https://t.co/5FDOpXjukz #PrecisionMedicine #caxtx #openaccess - view on twitter
Support our Efforts Make a donation Please select a donation amount or enter other amount. Please enter a valid amount. $25 $50 $100 $250...
Tomorrow! --> Please donate if you can. I am fundraising for the Leukemia & Lymphoma Society (LLS) - 2021 Scenic Shore Bike Tour (Sat, Sep 18, 2021) @lls_wisconsin @LLSusa https://t.co/eyu6cvwzAZ for team Philly 22 (2020 pic) https://t.co/eyu6cvwzAZ - view on twitter